Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$16.01 USD

16.01
12,370,961

+0.30 (1.91%)

Updated Aug 6, 2025 04:00 PM ET

Pre-Market: $16.33 +0.32 (2.00%) 8:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (164 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Company News For May 14, 2019

by Zacks Equity Research

Companies in the news are: TEVA, FF, PM and KRNT

Zacks Equity Research

The Zacks Analyst Blog Highlights: Teva, Amazon, Berkshire and JPMorgan

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Teva, Amazon, Berkshire and JPMorgan

Kinjel Shah headshot

Generic Drugmakers Face Antitrust Suit Alleging Price Fixing

by Kinjel Shah

Shares of generic drugmakers decline on allegations of price fixing by 44 states.

Sejuti Banerjea headshot

States Expand Suit Against Teva & Others, Shares Plunge

by Sejuti Banerjea

Teva Lawsuit scratches the surface of a much bigger price fixing racket in pharmaceuticals.

Zacks Equity Research

Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.

Zacks Equity Research

BioDelivery (BDSI) Stock Up on Q1 Earnings and Sales Beat

by Zacks Equity Research

BioDelivery (BDSI) incurs narrower-than-expected loss in Q1. Sales surpass the consensus mark. The company raises guidance for 2019.

Zacks Equity Research

Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View

by Zacks Equity Research

Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance

Zacks Equity Research

Mylan (MYL) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on the performance of Wixela Inhub, the newly launched biosimilars and other updates from Mylan (MYL)'s pipeline when the company shortly reports Q1 results.

Zacks Equity Research

Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down

by Zacks Equity Research

Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.

Kinjel Shah headshot

Teva (TEVA) Beats on Q1 Earnings, Misses Sales, Shares Down

by Kinjel Shah

Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Shares decline in pre-market trading.

Zacks Equity Research

Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut

by Zacks Equity Research

Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.

Zacks Equity Research

Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q1.

Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $15.14, marking a +0.93% move from the previous day.

Zacks Equity Research

Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on sales growth.

Zacks Equity Research

Allergan Falls as Supreme Court Dismisses Restasis Litigation

by Zacks Equity Research

Allergan's (AGN) key drug, Restasis' prospects hurt as the U.S. Supreme Court upholds the ruling of a lower court, which invalidated certain patents protecting the drug.

Zacks Equity Research

BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M

by Zacks Equity Research

BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca

Kinjel Shah headshot

Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU

by Kinjel Shah

Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.

Zacks Equity Research

Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig

by Zacks Equity Research

Novartis (NVS) sues Amgen as the latter issues termination notice for migraine drug.

Zacks Equity Research

Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe

by Zacks Equity Research

Teva's (TEVA) CGRP injection, Ajovy gets marketing approval in the EU after securing approval in the United States last year.

Zacks Equity Research

Novartis (NVS) Receives FDA Approval for MS Drug Mayzent

by Zacks Equity Research

Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.

Zacks Equity Research

Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.

Zacks Equity Research

Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision

by Zacks Equity Research

The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.

Zacks Equity Research

AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

by Zacks Equity Research

FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.

Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $16.64, marking a +0.79% move from the previous day.